A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease

Schreiber, S; Siegel, CA; Friedenberg, KA; Younes, ZH; Seidler, U; Bhandari, BR; Wang, K; Wendt, E; McKevitt, M; Zhao, S; Sundy, JS; Lee, SD; Loftus, EV

Schreiber, S (reprint author), Dept Internal Med 1, Med, Rosalind Franklin Str 12, D-24105 Kiel, Germany.; Schreiber, S (reprint author), Dept Internal Med 1, Rosalind Franklin Str 12, D-24105 Kiel, Germany.

JOURNAL OF CROHNS & COLITIS, 2018; 12 (9): 1014

Abstract

Background and Aims: Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of Crohn's disease and may serve as a potential biomarker. A ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索